The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
Abstract
Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC is characterized with unique tumor microenvironment (TME), which differs from other subtypes. TME is associated with induction of proliferation, angiogenesis, inhibition of apoptosis and immune system suppression, and drug resistance. Exosomes are promising nanovesicles, which orchestrate the TME by communicating with different cells within TME. The components of TME including transformed ECM, soluble factors, immune suppressive cells, epigenetic modifications and re-programmed fibroblasts together hamper antitumor response and helps progression and metastasis of TNBCs. Therefore, TME could be a therapeutic target of TNBC. The current review presents latest updates on the role of exosomes in modulation of TME, approaches for targeting TME and combination of immune checkpoint inhibitors and target chemotherapeutics. Finally, we also discussed various phytochemicals that alter genetic, transcriptomic and proteomic profiles of TME along with current challenges and future implications. Thus, as TME is associated with the hallmarks of TNBC, the understanding of the impact of different components can improve the clinical benefits of TNBC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bendinelli, P., Maroni, P., Matteucci, E., & Desiderio, M. A. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.403 · Cited by 32
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Membrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Becker, A., Thakur, B. K., Weiss, J. M., Kim, H. S., Peinado, H., & Lyden, D. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.009 · Cited by 2,003
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
The biology and function of exosomes in cancer
Kalluri, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81135 · Cited by 1,849
Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells
Mittelbrunn, M., Gutiérrez-Vázquez, C., Villarroya-Beltri, C., González, S., Sánchez-Cabo, F., González, M. Á., Bernad, A., & Sánchez-Madrid, F. (2011) · Nature Communications · doi:10.1038/ncomms1285 · Cited by 1,769
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
Morel, A.-P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., & Puisieux, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002888 · Cited by 1,645
Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis
Melo, S. A., Sugimoto, H., O’Connell, J. T., Kato, N., Villanueva, A., Vidal, A., Qiu, L., Vitkin, E., Perelman, L. T., Melo, C. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.005 · Cited by 1,531
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
The Hedgehog and Wnt signalling pathways in cancer
Taipale, J., & Beachy, P. A. (2001) · Nature · doi:10.1038/35077219 · Cited by 1,393
Interactions between cancer stem cells and their niche govern metastatic colonization
Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.-A., Delaloye, J.-F., & Huelsken, J. (2012) · Nature · doi:10.1038/nature10694 · Cited by 1,339
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Metabolic Regulation of T Lymphocytes
MacIver, N. J., Michalek, R. D., & Rathmell, J. C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095956 · Cited by 1,244
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,202
T cell metabolism drives immunity
Buck, M. D., O’Sullivan, D., & Pearce, E. L. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151159 · Cited by 1,179
Exosome Secretion: Molecular Mechanisms and Roles in Immune Responses
Bobrie, A., Colombo, M., Raposo, G., & Théry, C. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01225.x · Cited by 1,103
Liu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-Trevino, R., Shang, L., McDermott, S. P., Landis, M. D., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.11.009 · Cited by 1,053
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Human saliva, plasma and breast milk exosomes contain RNA: Uptake by macrophages
Lässer, C., Seyed Alikhani, V., Ekström, K., Eldh, M., Torregrosa Paredes, P., Bossios, A., Sjöstrand, M., Gabrielsson, S., Lötvall, J., & Valadi, H. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-9 · Cited by 899
Ziello, J. E., Jovin, I. S., & Huang, Y. (2007) · PubMed Central · Cited by 895
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Record, M., Carayon, K., Poirot, M., & Silvente-Poirot, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.10.004 · Cited by 852
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828
Subtypes of Breast Cancer Show Preferential Site of Relapse
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5644 · Cited by 813
Wnt/β-catenin signaling in cancer stemness and malignant behavior
Fodde, R., & Brabletz, T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.007 · Cited by 785
Tumor microenvironment: Sanctuary of the devil
Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 779
Ansieau, S., Bastid, J., Doreau, A., Morel, A.-P., Bouchet, B. P., Thomas, C., Fauvet, F., Puisieux, I., Doglioni, C., Piccinin, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.005 · Cited by 715
The immune score as a new possible approach for the classification of cancer
Galon, J., Pagès, F., Marincola, F. M., Thurin, M., Trinchieri, G., Fox, B. A., Gajewski, T. F., & Ascierto, P. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-1 · Cited by 628
Cancer Stem Cells: The Architects of the Tumor Ecosystem
Prager, B. C., Xie, Q., Bao, S., & Rich, J. N. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.12.009 · Cited by 587
Pattern of metastatic spread in triple-negative breast cancer
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 554
Kogure, T., Lin, W.-L., Yan, I. K., Braconi, C., & Patel, T. (2011) · Hepatology · doi:10.1002/hep.24504 · Cited by 551
The Biology of Cancer Exosomes: Insights and New Perspectives
Ruivo, C. F., Adem, B., Silva, M., & Melo, S. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0994 · Cited by 538
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome
Khramtsov, A. I., Khramtsova, G. F., Tretiakova, M., Huo, D., Olopade, O. I., & Goss, K. H. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091125 · Cited by 509
Exosomes: New players in cell–cell communication
Bang, C., & Thum, T. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.007 · Cited by 505
Breast Cancer: Current Molecular Therapeutic Targets and New Players
Nagini, S. (2017) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666160502122724 · Cited by 503
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Wang, T., Gilkes, D. M., Takano, N., Xiang, L., Luo, W., Bishop, C. J., Chaturvedi, P., Green, J. J., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410041111 · Cited by 493
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
Rody, A., Holtrich, U., Pusztai, L., Liedtke, C., Gaetje, R., Ruckhaeberle, E., Solbach, C., Hanker, L., Ahr, A., Metzler, D., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2234 · Cited by 460
Nabet, B. Y., Qiu, Y., Shabason, J. E., Wu, T. J., Yoon, T., Kim, B. C., Benci, J. L., DeMichele, A. M., Tchou, J., Marcotrigiano, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.031 · Cited by 452
The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective
Galon, J., Fridman, W.-H., & Pagès, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4806 · Cited by 447
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Gruosso, T., Gigoux, M., Manem, V. S. K., Bertos, N., Zuo, D., Perlitch, I., Saleh, S. M. I., Zhao, H., Souleimanova, M., Johnson, R. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci96313 · Cited by 439
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Moroishi, T., Hayashi, T., Pan, W.-W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A., & Guan, K.-L. (2016) · Cell · doi:10.1016/j.cell.2016.11.005 · Cited by 431
Exosomes in the tumor microenvironment as mediators of cancer therapy resistance
Li, I., & Nabet, B. Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0975-5 · Cited by 416
A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai, K., Hung, M., & Yamaguchi, H. (2016) · Europe PMC (PubMed Central) · Cited by 416
The fate of chemoresistance in triple negative breast cancer (TNBC)
O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 377
Geyer, F. C., Lacroix-Triki, M., Savage, K., Arnedos, M., Lambros, M. B., MacKay, A., Natrajan, R., & Reis-Filho, J. S. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.205 · Cited by 373
Xiao, Y., Ma, D., Zhao, S., Suo, C., Shi, J., Xue, M.-Z., Ruan, M., Wang, H., Zhao, J., Li, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3524 · Cited by 352
Understanding and treating triple-negative breast cancer
Carey, L., & Anders, C. (2021) · PubMed · doi:10.17615/85ph-f542 · Cited by 351
The Role of the Extracellular Matrix in Cancer Stemness
Nallanthighal, S., Heiserman, J. P., & Cheon, D.-J. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00086 · Cited by 344
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015) · Cancer · doi:10.1002/cncr.28914 · Cited by 333
Jung, H.-Y., Fattet, L., & Yang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3173 · Cited by 309
Targeting metabolism to regulate immune responses in autoimmunity and cancer
Patel, C. H., Leone, R. D., Horton, M. R., & Powell, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0032-5 · Cited by 306
Hu, K., Miao, L., Goodwin, T. J., Li, J., Liu, Q., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01522 · Cited by 292
Martin, L. J., Brambrink, A. M., Lehmann, C., Portera‐Cailliau, C., Koehler, R., Rothstein, J., & Traystman, R. J. (1997) · Annals of Neurology · doi:10.1002/ana.410420310 · Cited by 272
Breast Cancer Subtypes Predispose the Site of Distant Metastases
Soni, A., Ren, Z., Hameed, O., Chanda, D., Morgan, C. J., Siegal, G. P., & Wei, S. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpyo5fsv3upexs · Cited by 265
Binding and Fusion of Extracellular Vesicles to the Plasma Membrane of Their Cell Targets
Prada, I., & Meldolesi, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081296 · Cited by 264
Exosomes are endogenous nanoparticles that can deliver biological information between cells
Sun, D., Zhuang, X., Zhang, S., Deng, Z.-B., Grizzle, W., Miller, D., & Zhang, H.-G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.002 · Cited by 250
The role of the myofibroblast in tumor stroma remodeling
Otranto, M., Sarrazy, V., Bonté, F., Hinz, B., Gabbiani, G., & Desmouliere, A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20377 · Cited by 250
Exosome in Tumour Microenvironment: Overview of the Crosstalk between Normal and Cancer Cells
Roma-Rodrigues, C., Fernandes, A. R., & Baptista, P. V. (2014) · BioMed Research International · doi:10.1155/2014/179486 · Cited by 245
O’Brien, K., Rani, S., Corcoran, C., Wallace, R., Hughes, L., Friel, A. M., McDonnell, S., Crown, J., Radomski, M. W., & O’Driscoll, L. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.01.017 · Cited by 239
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 237
Exosome: emerging biomarker in breast cancer
Jia, Y., Chen, Y., Wang, Q., Jayasinghe, U., Luo, X., Wei, Q., Wang, J., Xiong, H., Chen, C., Xu, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16684 · Cited by 234
Elbaz, M., Nasser, M. W., Ravi, J., Wani, N. A., Ahirwar, D. K., Zhao, H., Oghumu, S., Satoskar, A. R., Shilo, K., Carson, W. E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.12.010 · Cited by 232
Sihto, H., Lundin, J., Lundin, M., Lehtimäki, T., Ristimäki, A., Holli, K., Sailas, L., Kataja, V., Turpeenniemi-Hujanen, T., Isola, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2944 · Cited by 229
Wong, C. C.-L., Zhang, H., Gilkes, D. M., Chen, J., Wei, H., Chaturvedi, P., Hubbi, M. E., & Semenza, G. L. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0855-y · Cited by 225
Burugu, S., Asleh-Aburaya, K., & Nielsen, T. O. (2017) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 222
Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells
Yang, J., Cao, Y., Sun, J., & Zhang, Y. (2010) · Medical Oncology · doi:10.1007/s12032-009-9344-3 · Cited by 219
Contribution of MyD88 to the Tumor Exosome-Mediated Induction of Myeloid Derived Suppressor Cells
Liu, Y., Xiang, X., Zhuang, X., Zhang, S., Liu, C., Cheng, Z., Michalek, S., Grizzle, W., & Zhang, H.-G. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090777 · Cited by 218
Zhou, X., Ye, F., Yin, C., Zhuang, Y., Yue, G., & Zhang, G. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430309 · Cited by 215
Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer
Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Wevers, E., Schwartz, T., Hunborg, P., Varvares, M. A., Hoft, D. F., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201892 · Cited by 214
mTOR Regulation of Glycolytic Metabolism in T Cells
Salmond, R. J. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00122 · Cited by 211
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12658 · Cited by 207
Therapeutic targets of triple‐negative breast cancer: a review
Jamdade, V. S., Sethi, N., Mundhe, N. A., Kumar, P., Lahkar, M., & Sinha, N. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13211 · Cited by 205
Triple-Negative Breast Cancer and the Potential for Targeted Therapy
Jhan, J.-R., & Andrechek, E. R. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0117 · Cited by 205
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy
Klein, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00367 · Cited by 196
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
Tahmasebi Birgani, M., & Carloni, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020405 · Cited by 193
Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy
Wang, B., Tian, T., Kalland, K.-H., Ke, X., & Qu, Y. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.008 · Cited by 192
Stiff, A., Trikha, P., Wesolowski, R., Kendra, K., Hsu, V., Uppati, S., McMichael, E., Duggan, M., Campbell, A., Keller, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1490 · Cited by 188
Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., Albarracin, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5281 · Cited by 188
Liubomirski, Y., Lerrer, S., Meshel, T., Rubinstein-Achiasaf, L., Morein, D., Wiemann, S., Körner, C., & Ben-Baruch, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00757 · Cited by 184
Thakur, R., Trivedi, R., Rastogi, N., Singh, M., & Mishra, D. P. (2015) · Scientific Reports · doi:10.1038/srep10194 · Cited by 183
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance
Yu, T., Department of Breast Surgery, F. U. S. C. C., Di, G., & Department of Oncology, S. M. C. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.03.10 · Cited by 179
Li, Y., Liang, Y., Sang, Y., Song, X., Zhang, H., Liu, Y., Jiang, L., & Yang, Q. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0030-7 · Cited by 179
Hwang, K.-T., Kim, J., Jung, J., Chang, J. H., Chai, Y. J., Oh, S. W., Oh, S., Kim, Y. A., Park, S. B., & Hwang, K. R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2782 · Cited by 179
Boulding, T., McCuaig, R., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17913-x · Cited by 174
Alarming Burden of Triple-Negative Breast Cancer in India
Thakur, K. K., Bordoloi, D., & Kunnumakkara, A. B. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.07.013 · Cited by 167
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Leary, M., Heerboth, S., Lapinska, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 165
Nair, V. S., Salhat, H. E., Taha, R. Z., John, A., Ali, B. R., & Elkord, E. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0512-1 · Cited by 163
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Liu, Y., Burness, M. L., Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R., Brooks, M. D., Shang, L., Fox, A., Luther, T. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1348 · Cited by 162
Dysfunctional T cell metabolism in the tumor microenvironment
Beckermann, K. E., Dudzinski, S. O., & Rathmell, J. C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.003 · Cited by 159
Kirkland, S. C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605143 · Cited by 158
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
Wein, L., & Loi, S. (2017) · The Breast · doi:10.1016/j.breast.2017.06.023 · Cited by 158
Sormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 153
Tumor microenvironment-mediated chemoresistance in breast cancer
Velaei, K., Samadi, N., Brazvan, B., & Rad, J. S. (2016) · The Breast · doi:10.1016/j.breast.2016.09.002 · Cited by 149
Tumor Microenvironment: A New Treatment Target for Cancer
Tsai, M., Chang, W., Huang, M., & Kuo, P. (2014) · ISRN Biochemistry · doi:10.1155/2014/351959 · Cited by 148
Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells
Jung, K. O., Youn, H., Lee, C., Kang, K. W., & Chung, J. (2016) · Oncotarget · doi:10.18632/oncotarget.14247 · Cited by 148
Piao, Y. J., Kim, H. S., Hwang, E. H., Woo, J., Zhang, M., & Moon, W. K. (2017) · Oncotarget · doi:10.18632/oncotarget.23238 · Cited by 146
Grither, W. R., & Longmore, G. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805020115 · Cited by 142
The hedgehog pathway in triple‐negative breast cancer
Habib, J. G., & O’Shaughnessy, J. (2016) · Cancer Medicine · doi:10.1002/cam4.833 · Cited by 140
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Conciatori, F., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., Milella, M., & Ciuffreda, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082453 · Cited by 138
Cancer Stem Cells in Triple-Negative Breast Cancer: a Potential Target and Prognostic Marker
O’Conor, C. J., Chen, T. Y., González, I., Cao, D., & Peng, Y. S. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0398 · Cited by 132
Reactive Astrocytes in Brain Metastasis
Wasilewski, D., Priego, N., Torre, C. F., & Valiente, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00298 · Cited by 131
Jones, L., Broz, M. L., Ranger, J. J., Ozcelik, J., Ahn, R., Zuo, D., Ursini‐Siegel, J., Hallett, M. T., Krummel, M. F., & Muller, W. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2770 · Cited by 128
Charepalli, V., Reddivari, L., Radhakrishnan, S., Vadde, R., Agarwal, R., & Vanamala, J. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.005 · Cited by 127
Udler, M. S., Meyer, K. B., Pooley, K. A., Karlins, E., Struewing, J. P., Zhang, J., Doody, D. R., MacArthur, S., Tyrer, J. P., Pharoah, P. D. P., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp078 · Cited by 127
MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer
Zhao, L., Sun, Y., Hou, Y., Peng, Q., Wang, L., Luo, H., Tang, X., Zeng, Z., & Liu, M. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.005 · Cited by 126
LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response
Serganova, I. S., Cohen, I., Vemuri, K., Shindo, M., Maeda, M., Mane, M. M., Moroz, E., Khanin, R., Satagopan, J. M., Koutcher, J. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203965 · Cited by 123
Fix, L. N., Shah, M., Efferth, T., Farwell, M. A., & Zhang, B. (2010) · PubMed · Cited by 122
Vadde, R., Sarojamma, V., Jinka, R., Merchant, N., Bramhachari, P. V., & Nagaraju, G. P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.025 · Cited by 121
Self-citationRegulation of CD8+ T Cells and Antitumor Immunity by Notch Signaling
Tsukumo, S., & Yasutomo, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00101 · Cited by 121
Wei, W., Tweardy, D. J., Zhang, M., Zhang, X., Landua, J. D., Petrovic, I., Bu, W., Roarty, K. P., Hilsenbeck, S. G., Rosen, J. M., et al. (2014) · Stem Cells · doi:10.1002/stem.1752 · Cited by 119
Deshmukh, S. K., Srivastava, S. K., Bhardwaj, A., Singh, A. P., Tyagi, N., Marimuthu, S., Dyess, D. L., Zotto, V. D., Carter, J. E., & Singh, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3591 · Cited by 119
EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Son, J. Y., Park, S.-Y., Kim, S., Lee, S. J., Park, S.-A., Kim, M.-J., Kim, S. W., Kim, D., Nam, J., & Sheen, Y. Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0903 · Cited by 116
Ozawa, P. M. M., Alkhilaiwi, F., Cavalli, I. J., Malheiros, D., Ribeiro, E. M. D. S. F., & Cavalli, L. R. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4925-5 · Cited by 116
Li, Y., Xiao, Y., Lin, H.-P., Reichel, D., Bae, Y., Lee, E. Y., Jiang, Y., Huang, X., Yang, C., & Wang, Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.019 · Cited by 116
The fibromatosis signature defines a robust stromal response in breast carcinoma
Beck, A. H., Espinosa, Í., Gilks, C. B., van de Rijn, M., & West, R. B. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.31 · Cited by 113
Hossain, F. M., Sorrentino, C., Uçar, D. A., Peng, Y., Matossian, M. D., Wyczechowska, D. D., Crabtree, J. S., Zabaleta, J., Morello, S., Valle, L. D., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00575 · Cited by 113
Racioppi, L., Nelson, E. R., Huang, W., Mukherjee, D., Lawrence, S. A., Lento, W. E., Masci, A. M., Jiao, Y., Park, S. H., York, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10424-5 · Cited by 109
Targeting tumour microenvironment by tyrosine kinase inhibitor
Tan, H.-Y., Wang, N., Lam, W., Guo, W., Feng, Y., & Cheng, Y.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0800-6 · Cited by 107
The Role of Extracellular Vesicles: An Epigenetic View of the Cancer Microenvironment
Qian, Z., Shen, Q., Yang, X., Qiu, Y., & Zhang, W. (2015) · BioMed Research International · doi:10.1155/2015/649161 · Cited by 107
A Mutant Receptor Tyrosine Phosphatase, CD148, Causes Defects in Vascular Development
Takahashi, T., Takahashi, K., John, P. L. S., Fleming, P. A., Tomemori, T., Watanabe, T., Abrahamson, D. R., Drake, C. J., Shirasawa, T., & Daniel, T. O. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1817-1831.2003 · Cited by 105
Tan, A. H. Y., Tu, W., McCuaig, R., Hardy, K., Donovan, T., Tsimbalyuk, S., Forwood, J. K., & Rao, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01351 · Cited by 104
Bhola, N. E., Jansen, V. M., Koch, J. P., Li, H., Formisano, L., Williams, J. A., Grandis, J. R., & Arteaga, C. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1640-t · Cited by 103
Wang, B., Zhang, Y., Ye, M., Wu, J., Ma, L., & Chen, H. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190819151946 · Cited by 100
Budişan, L., Gulei, D., Zănoagă, O., Irimie, A. I., Chira, S., Braicu, C., Gherman, C. D., & Berindan‐Neagoe, I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061178 · Cited by 98
Epigenetic Control of the Tumor Microenvironment
Marks, D. L., Olson, R. L., & Fernández-Zapico, M. E. (2016) · Epigenomics · doi:10.2217/epi-2016-0110 · Cited by 95
Valette, M., Poitou, C., Beyec, J. L., Bouillot, J., Clément, K., & Czernichow, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048221 · Cited by 92
Kuo, W.-Y., Hwu, L., Wu, C.-Y., Lee, J.-S., Chang, C., & Liu, R.-S. (2017) · Theranostics · doi:10.7150/thno.16827 · Cited by 92
Tumor-derived exosomes, microRNAs, and cancer immune suppression
Graner, M. W., Schnell, S. M., & Olin, M. R. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0689-6 · Cited by 92
Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment
García-Gómez, A., Rodríguez‐Ubreva, J., & Ballestar, E. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.013 · Cited by 91
Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers
Dréan, A., Williamson, C. T., Brough, R., Brandsma, I., Menon, M. R., Konde, A., García-Murillas, I., Pemberton, H. N., Frankum, J. R., Rafiq, R., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0098 · Cited by 90
Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer
Hunter, S., Nault, B., Ugwuagbo, K. C., Maiti, S., & Majumder, M. (2019) · Cancers · doi:10.3390/cancers11070938 · Cited by 90
Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
He, J., Lee, H., Saha, S., Ruan, D., Guo, H., & Chan, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1512-6 · Cited by 88
Irey, E. A., Lassiter, C. M., Brady, N. J., Chuntova, P., Wang, Y., Knutson, T. P., Henzler, C. M., Chaffee, T. S., Vogel, R. I., Nelson, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816410116 · Cited by 87
Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence
Das, D. M., & Law, S. K. A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.08.011 · Cited by 83
3,3′-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation
Jin, Y. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0985-0 · Cited by 82
Adams, A., Warner, K. A., Pearson, A. T., Zhang, Z., Kim, H. S., Mochizuki, D., Basura, G. J., Helman, J. I., Mantesso, A., CASTILHO, R. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5782 · Cited by 81
Kia, V., Paryan, M., Mortazavi, Y., Biglari, A., & Mohammadi‐Yeganeh, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27850 · Cited by 81
Suh, H. N., & Han, H. J. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22697 · Cited by 80
Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer
Kar, S., Sengupta, D., Deb, M., Shilpi, A., Parbin, S., Rath, S. K., Pradhan, N., Rakshit, M., & Patra, S. K. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-20 · Cited by 79
Sulaiman, A., McGarry, S., Li, L., Jia, D., Ooi, S., Addison, C., Dimitroulakos, J., Arnaout, A., Nessim, C., Yao, Z., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12167 · Cited by 79
Clift, R., Souratha, J., Garrovillo, S. A., Zimmerman, S. J., & Blouw, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3060 · Cited by 79
Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., Chang, P.-J., Schackmann, E. A., Hartman, A., Ford, J. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2174 · Cited by 77
Chen, C., Lu, Y., Cheng, A., Huang, C., Kuo, W., Wang, M., Chao, M., Chen, I., Kuo, C.-W., Lu, T., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0123 · Cited by 77
The metastatic microenvironment of breast cancer: Clinical implications
Coleman, R. E., Gregory, W. M., Marshall, H. C., Wilson, C., & Holen, I. (2013) · The Breast · doi:10.1016/j.breast.2013.07.010 · Cited by 76
S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy
Rostami, N., Nikkhoo, A., Ajoolabady, A., Azizi, G., Hojjat‐Farsangi, M., Ghalamfarsa, G., Yousefi, B., Yousefi, M., & Jadidi‐Niaragh, F. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00401-5 · Cited by 76
Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer
Holl, E. K., Frazier, V., Landa, K., Beasley, G. M., Hwang, E. S., & Nair, S. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01767 · Cited by 74
Vadde, R., Radhakrishnan, S., Reddivari, L., & Vanamala, J. (2015) · BioMed Research International · doi:10.1155/2015/649263 · Cited by 72
Tumor-derived extracellular vesicles in breast cancer: From bench to bedside
Wang, H., & Gires, O. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.012 · Cited by 72
A Review of the Role of Wnt in Cancer Immunomodulation
Goldsberry, W. N., Londoño, A. I., Randall, T. D., Norian, L. A., & Arend, R. C. (2019) · Cancers · doi:10.3390/cancers11060771 · Cited by 70
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
Márquez‐Garbán, D. C., Deng, G., Comin-Anduix, B., Garcia, A. J., Xing, Y., Chen, H., Cheung-Lau, G. C., Hamilton, N. M., Jung, M. E., & Pietras, R. J. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105415 · Cited by 70
Liubomirski, Y., Lerrer, S., Meshel, T., Morein, D., Rubinstein-Achiasaf, L., Sprinzak, D., Wiemann, S., Körner, C., Ehrlich, M., & Ben‐Baruch, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00804 · Cited by 68
The Role of Wnt Signaling In Cancer and Stem Cells
Reguart, N., He, B., Tarón, M., You, L., Jablons, D. M., & Rosell, R. (2005) · Future Oncology · doi:10.2217/14796694.1.6.787 · Cited by 66
Deshmukh, S. K., Srivastava, S. K., Tyagi, N., Ahmad, A., Singh, A. P., AL-Ghadhban, A., Dyess, D. L., Carter, J. E., Dugger, K. J., & Singh, S. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx037 · Cited by 66
Hannafon, B. N., Gin, A. L., Xu, Y.-F., Bruns, M., Calloway, C. L., & Ding, W. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0325-7 · Cited by 66
Bezombes, C., Fournié, J., & Laurent, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0154 · Cited by 64
Klymenko, Y., & Nephew, K. P. (2018) · Cancers · doi:10.3390/cancers10090295 · Cited by 64
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
O’Meara, T. A., Safonov, A. M., Casadevall, D., Qing, T., Silber, A. L. M., Killelea, B. K., Hatzis, C., & Pusztai, L. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05156-5 · Cited by 63
Willumsen, N., Thomsen, L. B., Bager, C. L., Jensen, C., & Karsdal, M. A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2074-z · Cited by 60
Park, C., Min, K. N., Son, J., Park, S.-Y., Nam, J., Kim, D., & Sheen, Y. Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.006 · Cited by 59
Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations
Chan, M. M.-Y., Chen, R., & Fong, D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.034 · Cited by 59
Current challenges in the management of breast cancer brain metastases
O'Sullivan, C. C., Davarpanah, N. N., Abraham, J., & Bates, S. E. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.006 · Cited by 58
Wu, S., Wang, Y., Yuan, Z., Wang, S., Du, H., Liu, X., Wang, Q., & Zhu, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9664 · Cited by 55
Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer
Rhodes, L. V., Tilghman, S. L., Boué, S. M., WANG, S., Khalili, H. S., Muir, S. E., Bratton, M. R., Zhang, Q., Wang, G., Burow, M. E., et al. (2011) · Oncology Letters · doi:10.3892/ol.2011.460 · Cited by 53
Suh, K. J., Sung, J. H., Kim, J. W., Han, S.-H., Lee, H. S., Min, A., Kang, M. H., Kim, J. E., Kim, J., Kim, S. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19194 · Cited by 53
Yardley, D. A., Ward, P. J., Daniel, B. R., Eakle, J. F., Lamar, R. E., Lane, C. M., & Hainsworth, J. D. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.006 · Cited by 52
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses
Hossain, F. M., Majumder, S., Uçar, D. A., Rodrı́guez, P. C., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01288 · Cited by 51
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Novel Biomarkers for Personalized Cancer Immunotherapy
Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 51
Li, L., Sapkota, M., Kim, S.-W., & Soh, Y. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.032 · Cited by 50
Horizons of nanotechnology applications in female specific cancers
Rajitha, B., Malla, R. R., Vadde, R., Kasa, P., Prasad, G. L. V., Farran, B., Kumari, S., Pavitra, E., Kamal, M. A., Raju, G. S. R., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.005 · Cited by 47
Self-citationFAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer
Pan, M., Hou, M., Ou‐Yang, F., Wu, C., Chang, S., Hung, W., Yip, H., & Luo, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010038 · Cited by 46
Wang, X., Brea, L. T., & Yu, J. (2019) · PubMed · Cited by 45
Hill, B. S., Sarnella, A., Capasso, D., Comegna, D., Gatto, A. D., Gramanzini, M., Albanese, S., Saviano, M., Zaccaro, L., & Zannetti, A. (2019) · Cancers · doi:10.3390/cancers11020139 · Cited by 43
Mathot, P., Grandin, M., Devailly, G., Souazé, F., Cahais, V., Morán, S., Campone, M., Herceg, Z., Esteller, M., Juin, P. P., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.88 · Cited by 40
Cited by
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Liu, R., Wang, R., Zhao, M., Liu, Y., Zhu, X., Wu, X., Du, S., Gu, Z., & Du, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101997 · Cited by 23
Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer
Yousafzai, N. A., El Khalki, L., Wang, W., Szpendyk, J., & Sossey-Alaoui, K. (2024) · Cancers · doi:10.3390/cancers16050883 · Cited by 20
Metadata
- Authors
- Deepak, K. G. K., Vempati, R., Nagaraju, G. P., Dasari, V. R., S., N., Rao, D. N., & Malla, R. R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 153
- Pages
- 104683
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W3005410912
- Cited by
- 614
- References
- 232
- FWCI
- 21.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.